Introduction
Venous thromboembolism (VTE) is a multifactorial disease with an incidence of 1 per 1000 and a high mortality of about 30 % within 30 days [1] . The manifestation of VTE depends on a complex balance between possible congenital or/and acquired risk factors such as anti-phospholipid antibody syndrome, hyperhomocysteinemia due to vitamin deficiency, activated protein C resistance without factor V Leiden mutation and increased factor Prolactin Receptor Signaling during Platelet Activation VIII [2, 3] . The known congenital risk factors for VTE include antithrombin, protein C, protein S deficiencies and especially the activated protein C resistance phenomenon attributable to the presence of the factor V Leiden mutation. The prothrombin G20210A mutation results in hyperprothrombinemia and hyperhomocysteinemia. Further conditions known to raise the risk for VTE are pregnancy [4, 5] as well as tumors, increasing age, male gender, surgery, and trauma.
In a recent study, we demonstrated that hyperprolactinemia causes increased platelet aggregation via potentiation of ADP effects both in vitro and in vivo [6] . Moreover, our data indicated that prolactin may be a physiological cofactor for platelet activation in the delicate coagulation balance during pregnancy and puerperium. Hyperprolactinemia is part of the physiological preparation for delivery and breast-feeding in pregnancy or puerperium where an increased risk for VTE has been reported [4, 5] . In another situation also associated with hyperprolactinemia, treatment with antipsychotic drugs [7] , an increased incidence of VTE has been documented [8] . Therefore, we hypothesized that changes of prolactin might contribute to the hypercoagulable state in patients with VTE by causing the activation of platelets. However, possible associations between hyperprolactinemia and VTE has not been systematically investigated up to now, and epidemiological data of VTE in other hyperprolactinemic states such as prolactinoma still need evaluated.
In an attempt to investigate the possible influence of prolactin on VTE, we compared prolactin levels in healthy subjects, patients with VTE and congenital risk factors and patients with VTE but neither congenital nor acquired risk factors for VTE. Furthermore, we investigated the incidence of VTE in prolactinoma patients. The present study demonstrates that patients with VTE without congenital or acquired risk factors have higher levels of prolactin than those with congenital risk factors or healthy controls. This indicates that prolactin may be a candidate for an acquired VTE risk factor. This hypothesis is supported by the demonstration of higher VTE incidence in prolactinoma patients than in the general population. Furthermore, we will demonstrate the expression of the short form of the prolactin receptor on platelets and characterize the molecular mechanism of prolactin receptor signaling during platelet activation.
Subjects and Methods
Experimental subjects 194 consecutive VTE patients with a congenital risk (group A, see below) and VTE patients without a congenital or acquired risk (group B, see below) for VTE were investigated for prolactin values. Patients with VTE were assigned to group A or B retrospectively. Group A had 96 patients (51 female, 45-male, age: 50 16 years) with VTE and heterozygous (n = 61) or homozygous (n = 5) factor V Leiden mutations and prothrombin G20210A mutations (n = 34). Group B had 98 patients (66 female, 32 male, age: 54 13 years) with VTE without congenital or acquired risk factor for VTE. Factor V Leiden mutation, prothrombin G20210A mutation, antithrombin-, protein C-, protein-S deficiency, activated protein C resistance phenomenon, hyperhomocysteinemia, anti-phospholipid antibodies and increased factor VIII levels were excluded as previously reported [9] . Plasma aliquots of VTE patients were stored after initial investigation at -80 8C until prolactin determination. 100 healthy, sex and age matched people without history of VTE served as healthy controls (Group C in Fig. 1 ) as previously reported [6] .
In a retrospective study, we evaluated the documented incidence of VTE in 136 consecutive prolactinoma patients (79 female, 57-male; age: 39 13 years). The diagnosis of prolactinoma based on histological examination or on prolactin levels above 10-fold of the upper limit of the PRL assay at diagnosis and mostly tumor shrinkage in magnetic resonance imaging by dopamine agonist therapies. After screening our 136 patients, 62 cases (38 female, 24 male, age: 37 12.2 years) were identified that had completely documented case histories and database for diagnostics tests during the time of hyperprolactinemia and observation. We evaluated the period of hyperprolactinemia in these 62 patients, which was defined as time in years between first symptoms of hyperprolactinemia or tumor size and documented normalization of PRL by therapy. The summarized period of hyperprolactinemia was 359 years for the 62 patients (5.8 4.6 years per patient). Three of the 62 patients suffered from VTE (1 pulmonary embolism and 2 deep vein thrombosis) during the period of hyperprolactinemia. Fig. 1 Prolactin levels in patients with VTE without congenital or aquired risk factors are significantly higher than in patients with VTE and congenital risk factors or healthy controls. The PRL values of VTE patients with congenital risk factors (a) were compared to VTE patients without congenital or acquired risk factors (b) and healthy controls (c) by the Mann-Whitney U-test. Box plots represent 25th and 75th percentiles, error bars minimum or maximum of PRL values, the dots represent values above the maximum of PRL values of the group. P values are given above the plots.
Materials and Methods
Monoclonal antibody recognizing the short 43kDa isoform of the prolactin receptor family was obtained from Alexis Biochemicals. Monoclonal antibody recognizing the a-, b-and g-isoforms of protein kinase C (pan-PKC) was obtained from Abcam Ltd. Polyclonal antibody to identify phosphorylation of a, b-I, b-II, g and d PKC isoforms at the C-terminal phosphorylation site corresponding to serine 660 in PKC b-II was obtained from New England BioLabs. Serotonin and purified recombinant human prolactin were purchased from Sigma.
Determination of serum prolactin
The plasma prolactin values of healthy controls and patients with VTE were analyzed by Axsym Prolactin Assay (Abbott, USA). Serum prolactin values were considered normal if they were < 580 mU/l (24.2 ng/ml) in females and < 450 mU/l (18.77 ng/ml) in males. This assay was performed according to the manufacturer's instructions as previously reported [6] .
Isolation and stimulation of human platelets
Blood collection from informed healthy human volunteers and preparation of platelet-rich plasma and washed platelets were prepared as described [10] . Washed platelets (1 10 9 platelets/ ml) were resuspended in PBS with 1 mM EDTA and 5.5 mM Dglucose. CaCl 2 (1 mM) and MgCl 2 (1 mM) were added to platelet suspension before preincubation with buffer, 1000 mU/l or 5000 mU/l of recombinant PRL (final concentration) for 5 min at 37 8C, followed by activation with 4 M ADP. At various time points, aliquots of the cell suspension were removed and reaction was stopped by addition of SDS stop solution for Western blot analysis.
Platelet aggregation assay
Platelet aggregation was determined in a PAP-4 aggregometer (Biodata) as described [11] . Briefly, aggregation was measured in 300 l samples of PRP that were preincubated with buffer, 1000 mU/l or 5000 mU/l PRL (final concentration) for 5 min at 37 8C and stimulated with ADP (2 M), Epinephrine (0.7 M), serotonin (5 M) or a combination of these substances. The degree of platelet aggregation was measured as percent of change in light transmission of PRP in relation to the light transmission of platelet poor plasma (PPP).
Western blotting and quantification
Western blotting was performed as described [10] . Samples were separated on 9 % SDS-polyacrylamide gels, blotted onto polyvinylidine fluoride (PVDF) membranes that were blocked by 6 % phosphatase-free milk powder in Tris-buffered saline with 0.05 % Tween-20 (TBS/Tween). Proteins were stained with anti-PRL-R antibody (1 : 500 dilution), anti-phospho-PKC (1 : 1000 dilution) or anti-PKC pan (phosphorylation state independent) (1 : 1000) antibodies overnight at 4 8C. Immunoreactivity was determined using peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG (1 : 3000 dilution for both of these antibodies) and the ECL chemiluminescence reaction. Intensity of Western blot bands was quantified as described previously [10] .
Flow cytometry
Flow cytometric analysis of intracellular VASP phosphorylation in platelets was performed as previously described [10] . Briefly, platelet-rich plasma was incubated for 3 min with 0.5 M PG-E1 with or without 20 M ADP, 1 M epinephrine, 1000 mU/l or 5000 mU/l prolactin or 5 M serotonin. The reaction was stopped by addition of 3 % final concentration of methanol-free formaldehyde followed by permeabilization by 0.2 % Triton X-100 in phosphate-buffered saline. Staining was performed using the VASPSerine-157 phosphorylation-specific antibody (dilution) and fluorescein isothiocyanate (FITC)-conjugated, affinity-purified goat anti-mouse IgG (Sigma, St. Louis,MO). Data were analyzed at a low flow rate on a Becton Dickinson FACSCalibur with the settings described earlier [10] .
Statistical analysis
The Mann-Whitney U-test was used to compare the prolactin values between healthy controls, patients with VTE with congenital (group A) and without congenital and acquired risk factors (group B). Bonferroni correction was used for multiple comparisons. The incidence rate of VTE was calculated as the number of cases of thromboembolism during the period of hyperprolactinemia divided by the number of person-years. The risk ratios for thromboembolism during the period of hyperprolactinemia in comparison with the risk for thromboembolism of two populations [12, 13] were estimated at 95 % confidential intervals. The increase in PKC phosphorylation was tested by Student's t-test; p-values less than 0.05 were considered statistically significant. Data were analyzed using SPSS for Windows (release 9.0.1).
Results
Prolactin levels in patients with VTE without congenital or acquired risk factors are significantly higher than in patients with VTE and congenital risk factors or healthy controls
The mean values of PRL were 185 60 mU/l and 165 50 mU/l in the healthy controls and patients with congenital risk for VTE, respectively. These levels were not significantly different after Bonferroni correction (Fig. 1 , p = 0.075). In contrast, in patients with VTE but without congenital or acquired risk factors, the mean PRL value was 285 351 mU/l, therefore significantly higher than in those patients with congenital risk factors (p < 0.0001. Fig. 1 shows median, 25th and 75th percentile, maximum and minimum of prolactin values). Furthermore, the PRL values in 6 of the patients with VTE without risk factors were above the maximum in the group (PRL levels between 635 and 3028 mU/l; dots in Fig. 1 ).
Increased incidence of VTE in patients with prolactinoma
We found 6 patients with documented VTE in our series of 136 prolactinoma patients; three of them had also documented pulmonary embolism. A further 18/136 patients had indication for previous VTE, such as post-thrombotic syndrome. Complete documentation of case history and PRL levels was available in 62 of the 136 patients during the period of hyperprolactinemia. Three cases of VTE were documented in this subgroup with a total hyperprolactinemia history of 359 years (mean 5.8 4.6 years per patient). The incidence of 3 VTE during 359 years of hyperprolactinemia is significantly elevated compared to the documented annual incidence of VTE (627/342 000, RR = 4.7, 95 % CI 1.5 -14.5) or idiopathic VTE (230/1000 000, RR = 36.5 95 % CI 11.7 -114.1) in Caucasoid persons older than 18 years [12, 13] . Therefore, hyperprolactinemia in patients with prolactinoma is associated with an in increased risk for VTE.
A short isoform of prolactin receptors is present on human platelets Several prolactin receptors have been detected in extracts from various tissues and cell types; however, whether a receptor for prolactin is present on human platelets has not been elucidated. Using a monoclonal antibody recognizing a 43 kDa short isoform of the prolactin receptor family, we could demonstrate the presence of this receptor on human platelets (Fig. 2 a) . As a positive control, we used extracts from rat liver and human neutrophil granulocytes, both known to contain this prolactin receptor isoform [14, 15] .
ADP-induced platelet aggregation is potentiated by purified, recombinant human prolactin
We have demonstrated the potentiating effect of plasma from patients with high prolactin levels on ADP-induced platelet activation [6] . They exclude other substances in the plasma that could contribute to this effect; we incubated human platelets with purified, recombinant human prolactin. While low concentrations of ADP induced weak and reversible platelet aggregation, preincubation with 1000 mU/l or 5000 mU/l prolactin induced a dose-dependent potentiation of ADP-induced platelet aggregation leading to full platelet aggregation in the presence of 5000 mU/l prolactin (Fig. 2 b) . Incubation with prolactin alone did not induce platelet aggregation (Fig. 2 b) . No prolactin-mediated potentiation was detectable on thrombin-or collagen-induced platelet aggregation (data not shown).
Prolactin can substitute for Gq-protein-regulated signaling pathways necessary for human platelet aggregation Signaling events from both the platelet P2Y 1 ADP receptor (Gqprotein coupled) and the P2Y 12 ADP receptor (Gi-protein coupled) are essential for complete ADP-induced platelet aggregation [16, 17] . Analogous to P2Y 12 receptor activation, epinephrine acts on platelets via its a2a-adrenergic receptor that is coupled to Gi, whereas serotonin through the 5-hydroxytryptamine receptor subtype 2A stimulates Gq-regulated signaling pathways analogous to the P2Y 1 receptor [16, 18] . To characterize the molecular mechanism by which prolactin potentiates the platelet ADP response, we co-stimulated human platelets with prolactin and epinephrine or serotonin. While prolactin and epinephrine alone did not induce platelet aggregation, the combination of both substances resulted in complete platelet aggregation (Fig. 3 a) .
Incubation of platelets with serotonin resulted in very weak platelet aggregation (less than 20 %, Fig. 3 b) , and the combination of serotonin and prolactin did not increase platelet aggregation any further compared to serotonin alone (Fig. 3 b) . As a control, platelets were stimulated with both epinephrine and serotonin resulting in complete aggregation (Fig. 3 c) . These experiments indicate that prolactin-signaling pathways can substitute Gqregulated signaling pathways.
Platelet shape change is known to be induced by Gq-regulated signaling pathways ( [16] and model in Fig. 6 ). Analysis of shape change in our experiments revealed that only serotonin induced platelet shape change, whereas prolactin did not (Fig. 3 d) , indicating that prolactin receptors might not be directly linked to the Gq-protein but might signal through mechanisms downstream of Gq. A potential site of prolactin receptor signaling is protein kinase C, known to be one of the key enzymes in Gqregulated signaling cascades (Fig. 6 ).
ADP and prolactin synergistically activate protein kinase C To test this hypothesis, washed human platelets were incubated with buffer, prolactin (PRL), ADP, or both ADP and prolactin. Aliquots were removed at 1 and 3 minutes and analyzed by Western blot technique for phosphorylation of protein kinase C at the site corresponding to serine 660 in PKCb-II. Phosphorylation of that site correlates with PKC activity [19] . While ADP induced only a slight increase in PKC phosphorylation under these conditions, prolactin induced a significant stronger increase in PKC phosphorylation than ADP (Fig. 4) . Incubation with both prolactin and ADP resulted in an additive effect on PKC phosphorylation increasing PKC phosphorylation more than 50 % compared to ADP alone (p < 0.006, Fig. 4) . Prolactin does not stimulate Gi-regulated signaling pathways that inhibit adenylyl cyclase/cAMP-regulated pathways in human platelets Flow cytometry analysis of intracellular phosphorylation of the Vasodilator-stimulated phosphoprotein (VASP) is a useful tool to characterize the coupling of platelet receptors to Gi-proteins [10] . Incubation with PG-E 1 induced strong VASP phosphorylation at serine-157 in platelets. However, co-stimulation of platelets with PG-E 1 and ADP or epinephrine almost completely inhibited PG-E 1 /cAMP-induced VASP phosphorylation due to a wellcharacterized Gi-mediated inhibitory effect on adenylyl cyclase ( Fig. 5 and [10,11] ). In contrast, prolactin failed to inhibit PG-E 1 / cAMP-induced VASP phosphorylation -again indicating that prolactin is not linked to Gi-regulated signaling pathways (Fig. 5) . As expected and known, serotonin did not stimulate the Gi-regulated pathway, either ( [20] and Fig. 5 ).
Discussion
Beyond the well-known plasmatic factors, the pathogenesis of thrombosis involves complex platelet-leukocyte interactions whose details have not fully been elucidated [21] . P-selectin mediates rolling of platelets and leukocytes on activated endothelial cells. Recent data indicate that P-selectin interaction with a ligand stabilizes initial GP IIb/IIIa-fibrinogen interactions, thus allowing the formation of large stable platelet aggregates [22] . Furthermore, in the Pulmonary Embolism Prevention Trial (PEP), it was been demonstrated that aspirin could reduce VTE by at least a third throughout a period of increased risk [23] . These results, along with those of previous meta-analysis [24, 25] , suggest that the activation of platelets is an important initial step in the development of venous thrombosis. Up to now, the significance of activated platelets for the development of VTE has not been investigated systematically, whereas the influence of platelet activation on arterial thrombosis is undisputed.
In a recent study, we demonstrated a correlation between PRL levels and platelet activation in pregnant women and patients with hyperprolactinemic pituitary tumors [6] . The possible association between hyperprolactinemia and VTE has not been systematically investigated up to now; epidemiological data of VTE in patients with pituitary tumors are lacking. Now, we have found significantly higher PRL levels in VTE patients without congenital or acquired risk factors compared to patients with such risk factors or healthy controls. Most patients with idiopathic VTE showed PRL values that were still in the upper normal range. However, this finding corresponds to the dose-dependent increased platelet activation and aggregation by human PRL in vitro that already occurs within the normal plasma prolactin range ( Fig. 2 b and [6] ).
Moreover, hyperprolactinemic prolactinoma patients have a significantly higher incidence of VTE and of idiopathic VTE than the general population. We have used a very strict approach, counting only well-documented, safely diagnosed cases of VTE. All cases we have included were based on objective tests: duplex sonography or venography for deep vein thrombosis, pulmonary angiography, and helicoidal CT scan for pulmonary embolism. We excluded the 18 patients with some indication of previous VTE as post-thrombotic syndrome in our statistical analysis, which may have resulted in an underestimation of cases. Altogether, our epidemiological data suggest that hyperprolactinemia is a candidate for a novel acquired risk factor for VTE, especially idiopathic VTE, which might explain the increased risk for VTE in hyperprolactinemic states. Currently, we are investigating the influence of hyperprolactinemia in prolactinoma patients on the risk of VTE in a prospective trial. If we can confirm our hypothesis, we would conclude that the objective of therapy for hyperprolactinemia especially in prolactinoma patients should be the suppression of PRL levels in the lower normal range, not only a restoration of PRL levels to the upper normal range [26] to minimize the risk of VTE.
PRL-R is widely distributed in mammalian tissues and cells [27] . Multiple isoforms of membrane-bound PRL-R resulting from alternative splicing of the primary transcript have been identified. They differ in the length and composition in their cytoplasmic tails, and are referred to as short, intermediate or long forms of PRL-R with respect to their molecular weight, which ranges from 39 to 110 kDa depending on the cell type and the species investigated. In addition to membrane-anchored PRL-R, soluble isoforms have been identified, but whether they result from alternative splicing of the primary mRNA or proteolytic cleavage of membrane-bound PRL-R is yet unknown [28] . A 43 kDa short isoform of this receptor has been identified [14, 29] In human hematopoietic progenitor cells. Using an antibody directed against the short form of the PRL-R present in rat liver that cross-reacts with the human receptor, we have now demonstrated the presence of a short 43 kDa isoform of the PRL-R in human platelets (Fig. 2 a) .
To the best of our knowledge, functional effects and mechanisms of PRL action in platelets are unknown. In a recent study, we demonstrated that increased plasma PRL levels potentiate ADP effects on platelet P-Selectin expression and platelet aggregation [6] . There is very little in the way of data regarding functional effects and mechanisms of PRL action in platelets. In mammalian cells, PRL receptors are non-kinase receptors -their activation requires participation of receptor associated kinases known as janus kinases (JAK) [30, 31] . Dimerization of the receptor induces tyrosine phosphorylation and activation of the JAKs followed by phosphorylation of the receptor. JAK activation results also in phosphorylation of the cytoplasmic factor complex termed signal transducer and activator of transcription (STAT), which translocates into the nucleus and activates transcription of specific genes in mammalian cells [32, 33] . Important signaling molecules involved in platelet activation are regulated in other cell systems by PRL receptors, including the Ras/Raf/MAP kinase pathways [34 -36] as well as signaling molecules like PI-3 kinase, PLC gamma and PKC [37 -39] .
In platelets, the molecular mechanisms of the PRL action still have to be resolved. Several signaling molecules of PRL receptorregulated pathways in mammalian cells are also present in human platelets. Since there is clear evidence that PRL can influence signal transduction through G-protein-coupled receptors [40 -42] , we investigated effects of PRL on G-protein-regulated signaling pathways in platelet activation. ADP effects on platelets are mediated by at least two different G-protein-coupled receptors -P2Y 1 and P2Y 12 (formerly termed P2Y AC ) [16, 20, 43] . P2Y 1 is coupled to stimulatory Gq-proteins and activates phospholipase C, whereas P2Y 12 signals via a Gi protein that inhibits platelet adenylate cyclase function and lowers platelet cAMP [43] . Both receptor pathways are necessary for complete ADP-induced platelet aggregation [16, 17, 43] . ADP action on these receptors can be mimicked by receptors coupling to functional identical G-proteins. Serotonin, a weak platelet agonist, activates Gq-coupled signaling pathways, but not Gi ( [16, 17, 43] and Fig. 5 ). In contrast, epinephrine activates platelets through a Gi-protein, but not through Gq [16, 17] . Co-stimulation of platelets with prolactin and these substances demonstrates that prolactin does not signal through Gi-regulated pathways, but is able to substitute for Gq-regulated signaling pathways (Fig. 3) . The complex signaling mechanisms of prolactin need further investigation. Phosphorylation of PKC could be induced by activation of janus kinases, which induces a phosphorylation cascade involving PKC, thereby promoting platelet activation. It has been shown that thrombin activation of JAK3 in platelets is followed by tyrosine phosphorylation of STAT-1 and STAT-3. Inhibition of JAK3 prevented thrombin-induced platelet shape change, serotonin release and platelet aggregation [44] . It is very likely that the PRL receptor is not directly linked to a Gq-protein since incubation with PRL alone did not induce platelet shape change (Fig. 3 d) . Although it does not induce platelet aggregation, prolactin by itself induced PKC activation in platelets and increased ADP-induced activation of PKC in an additive way (Fig. 4 b) . Similar mechanisms of signaling have been shown for luteinized rat granulosa cells, in which PKC clearly is a downstream signaling molecule of the prolactin receptor [37] . Revealing the molecular mechanisms of prolactin signaling in human platelets will contribute to a better understanding of the thrombogenic effect of this hormone, and may allow new therapeutic strategies for the anti-thrombotic treatment in certain risk situations and thrombotic diseases.
